Variant Bio Expands Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular Disease

PartnershipPositive

AI Analysis

Summary

Variant Bio expanded its multi-year collaboration with Boehringer Ingelheim to apply its AI-powered Inference platform to cardiovascular disease target discovery, with total deal value potentially exceeding $250 million including upfront, platform access, and milestone payments.

Outcome Details

Expanded multi-year collaboration for cardiovascular target discovery using AI-powered Inference platform

Importance:7/10

Sentiment:

0.70

partnershipcollaborationcardiovasculartarget discoveryAI platformmilestone payments

Related Companies

$CBDY

Read the original article

Published by PR Newswire Biotech on September 23, 2026 12:00 PM

Read Original